Goldman Sachs Group Inc Bei Gene, Ltd. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 44,231 shares of BGNE stock, worth $10 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,231

Previous 70,255 37.04%

Holding current value

$10 Million

Previous $15.9 Million 37.04%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	N/A	-26,024 Reduced 37.04%	44,231 $10 Million
Q2 2025 Aug 14, 2025	SELL	N/A	-27,883 Reduced 28.41%	70,255 $15.9 Million
Q1 2025 May 09, 2025	BUY	$175.1 - $226.71 $8.88 Million - $11.5 Million	50,734 Added 107.02%	98,138 $22.2 Million
Q4 2024 Feb 11, 2025	BUY	$174.72 - $246.04 $2.93 Million - $4.12 Million	16,746 Added 54.62%	47,404 $8.76 Million
Q3 2024 Nov 14, 2024	SELL	$143.93 - $224.51 $7.26 Million - $11.3 Million	-50,468 Reduced 62.21%	30,658 $6.88 Million

Q2 2024 Aug 13, 2024	BUY	$129.52 - $174.32 $2.95 Million - $3.96 Million	22,741 Added 38.95%	81,126 $11.6 Million
Q1 2024 May 15, 2024	SELL	$141.8 - $181.47 $22.1 Million - $28.3 Million	-155,954 Reduced 72.76%	58,385 $9.13 Million
Q4 2023 Feb 13, 2024	BUY	$158.67 - $201.58 $21.7 Million - $27.5 Million	136,458 Added 175.21%	214,339 $38.7 Million
Q3 2023 May 14, 2024	SELL	$179.87 - $225.13 $24.5 Million - $30.7 Million	-136,458 Reduced 63.66%	77,881 $14 Million
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $1.25 Million - $1.56 Million	6,935 Added 9.78%	77,881 $14 Million
Q2 2023 May 14, 2024	BUY	$178.3 - $266.78 $843,537 - $1.26 Million	4,731 Added 7.14%	70,946 $12.6 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $843,537 - $1.26 Million	4,731 Added 7.14%	70,946 $12.6 Million
Q1 2023 May 14, 2024	SELL	$215.53 - $274.5 $458,216 - $583,587	-2,126 Reduced 3.11%	66,215 $14.3 Million
Q1 2023 May 11, 2023	SELL	$215.53 - $274.5 $458,216 - $583,587	-2,126 Reduced 3.11%	66,215 $14.3 Million
Q4 2022 May 14, 2024	SELL	$125.51 - $229.3 $27.2 Million - $49.6 Million	-216,353 Reduced 75.99%	68,341 $15 Million
Q4 2022 Feb 13, 2023	SELL	$125.51 - $229.3 $27.2 Million - $49.6 Million	-216,353 Reduced 75.99%	68,341 $15 Million
Q3 2022 May 14, 2024	BUY	$131.8 - $202.24 $5.46 Million - $8.37 Million	41,401 Added 17.02%	284,694 $38.4 Million
Q3 2022 Nov 10, 2022	BUY	$131.8 - $202.24 $5.46 Million - $8.37 Million	41,401 Added 17.02%	284,694 $38.4 Million
Q2 2022 May 14, 2024	BUY	$121.11 - $216.05 $3.51 Million - $6.26 Million	28,954 Added 13.51%	243,293 $39.4 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $559,164 - $997,502	4,617 Added 1.93%	243,293 $39.4 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $7.36 Million - $13.5 Million	50,236 Added 26.66%	238,676 $45 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $6.14 Million - $9.62 Million	24,701 Added 15.09%	188,440 $51.1 Million
Q3 2021 Nov 10, 2021	BUY	$249.6 - $403.14 $40.9 Million - $66 Million	163,739 New	163,739 $59.4 Million

Others Institutions Holding BGNE

# of Institutions

300

Shares Held

30.4M

Call Options Held

147K

Put Options Held

195K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Bei Gene, Ltd. Transaction History